Previous 10 | Next 10 |
La Jolla Pharmaceutical (NASDAQ:LJPC): Q2 GAAP EPS of $0.11 beats by $0.24. Revenue of $16.06M (+176.4% Y/Y) beats by $4.16M. Press Release For further details see: La Jolla Pharmaceutical EPS beats by $0.24, beats on revenue
La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2021 and hig...
La Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products. Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the...
Jiuzi Holdings (JZXN) +49%.GTT Communications (GTT) +28%.Community Bankers Trust Corporation (ESXB) +26% on merger agreement with United Bankshares.Tellurian (TELL) +26% on 10-year LNG sales deal with Vitol.Workhorse Group (WKHS) +16%.Auris Medical Holding (EARS) +14%.Blac...
La Jolla Pharmaceutical (LJPC) shares rise more than 10% during premarket trading after the company posted first-quarter revenue that beat Wall Street estimates.The company's total revenue increased 349.8% to $34.1M, beating analysts' estimate by $0.99M.La Jolla’s net in...
La Jolla Pharmaceutical (LJPC): Q1 GAAP EPS of $0.42 misses by $0.14.Revenue of $34.14M (+349.8% Y/Y) beats by $0.99M.As of March 31, 2021 and December 31, 2020, La Jolla had cash and cash equivalents of $38.6 million and $21.2 million, respectively.Press Release For further details see: ...
La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 202...
La Jolla Pharmaceutical (LJPC): Q4 GAAP EPS of -$0.13 beats by $0.21.Revenue of $11M (+51.7% Y/Y) beats by $0.86M.Press Release For further details see: La Jolla Pharmaceutical EPS beats by $0.21, beats on revenue
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended Dec...
Gainers: ArcLight Clean Transition (ACTCU) +80%.VOXX International (VOXX) +47%.BIOLASE (BIOL) +43%.Dolphin Entertainment (DLPN) +41%.ENGlobal (ENG) +39%.Zomedica (ZOM) +39%.IRIDEX (IRIX) +34%.AcelRx Pharmaceuticals (ACRX) +28%.La Jolla Pharmaceutical (LJPC) ...
News, Short Squeeze, Breakout and More Instantly...
La Jolla Pharmaceutical Company Company Name:
LJPC Stock Symbol:
NASDAQ Market:
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of L...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...